Wayfinders Wellness brings mental health first aid to Cochrane - CochraneNow

Researchers analysed data from more than 90 studies, which examined pharmaceutical company promotion to prescribersHanna Kuprevich/ Alamy Stock PhotoPromotional interactions between pharmaceutical companies and clinicians, including gifts and payments, are likely “associated with harmful outcomes”, a Cochrane review has suggested. Publishing the findings of the review, entitled ‘Pharmaceutical industry information and promotional strategies aimed at prescribers’ in the Cochrane Database of Systematic Reviews on 9 October 2026, the authors highlighted that such gifts were associated with “inappropriate prescribing”, an increase in the quantity of prescriptions and “probably” an increase in prescription costs. Gifts and payments were considered to include food and drink, consultancy payments, payments to cover travel expenses, and conference and other educational expenses. The authors analysed 93 studies of pharmaceutical company promotion to prescribers. Of these, 82 studies were conducted in the United States, while 11 studies were conducted in the European Union or the UK.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.